Bookmark
Forward
QuickView for Zaleplon (compound)
PubChem
| Name: | zaleplon |
|---|---|
| PubChem Compound ID: | 5719 |
| Molecular formula: | C17H15N5O |
| Molecular weight: | 305.334 g/mol |
| Synonyms: |
DEA No. 2781; CL 284,846; ZAL 846; Zaleplon (JAN/USAN); CL-284846; D00530; Acetamide, N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethyl-; Zaleplon [USAN:INN]; Sonata (TN); Sonata.
show more » |
DrugBank
Identification
| Name: | zaleplon |
|---|---|
| Name (isomeric): | DB00962 |
| Drug Type: | small molecule |
| Synonyms: |
DEA No. 2781
|
| Brand: | Sonata, Zalaplon |
| Category: | Hypnotics and Sedatives, Anxiolytics sedatives and hypnotics, Anticonvulsants |
| CAS number: | 151319-34-5 |
Pharmacology
| Indication: | For the treatment of short-term treatment of insomnia in adults. |
|---|---|
| Pharmacology: |
Zaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zaleplon is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GA...
show more » |
| Mechanism of Action: | Zaleplon exerts its action through subunit modulation of the GABABZ receptor chloride channel macromolecular complex. Zaleplon also binds selectively to the brain omega-1 receptor located on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding. |
| Absorption: | Absorption Zaleplon is rapidly and almost completely absorbed following oral administration. |
| Protein binding: | Approximately 60% (in vitro plasma protein binding). |
| Biotransformation: | Zaleplon is primarily metabolized by aldehyde oxidase. |
| Route of elimination: | Zaleplon is metabolized primarily by the liver and undergoes significant presystemic metabolism. After oral administration, zaleplon is extensively metabolized, with less than 1% of the dose excreted unchanged in urine. Renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose. |
| Half Life: | Approximately 1 hour |
| Clearance: | 1 L/h/kg |
| Toxicity: | Side effects include abdominal pain, amnesia, dizziness, drowsiness, eye pain, headache, memory loss, menstrual pain, nausea, sleepiness, tingling, weakness |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
Enzymes
